Latest news with #VYVGART®
Yahoo
8 hours ago
- Business
- Yahoo
High Growth Tech Stocks To Watch In Europe June 2025
As the European markets experience a boost, with the STOXX Europe 600 Index climbing by 0.90% amid easing inflation and supportive monetary policy from the European Central Bank, investors are increasingly focusing on high-growth sectors such as technology. In this environment, identifying promising tech stocks involves looking for companies that can leverage favorable economic conditions and technological advancements to drive substantial growth. Name Revenue Growth Earnings Growth Growth Rating Intellego Technologies 30.80% 45.66% ★★★★★★ Archos 21.07% 36.58% ★★★★★★ KebNi 21.51% 66.96% ★★★★★★ Pharma Mar 29.61% 44.92% ★★★★★★ Bonesupport Holding 29.14% 56.14% ★★★★★★ argenx 21.50% 26.61% ★★★★★★ Skolon 31.51% 99.52% ★★★★★★ Xbrane Biopharma 24.95% 56.77% ★★★★★★ Diamyd Medical 86.29% 93.04% ★★★★★★ Elliptic Laboratories 36.33% 78.99% ★★★★★★ Click here to see the full list of 226 stocks from our European High Growth Tech and AI Stocks screener. Let's explore several standout options from the results in the screener. Simply Wall St Growth Rating: ★★★★★★ Overview: argenx SE is a commercial-stage biopharma company focused on developing therapies for autoimmune diseases across several countries including the United States, Japan, China, and the Netherlands, with a market cap of €31.52 billion. Operations: argenx focuses on developing therapies for autoimmune diseases, generating revenue primarily from its biotechnology segment, which reported $2.64 billion. The company's operations span multiple countries, including the United States, Japan, China, and the Netherlands. argenx SE has demonstrated remarkable growth with a surge in revenue to $807.37 million, doubling from the previous year's $412.51 million, alongside transitioning from a net loss to a substantial net income of $169.47 million. This financial turnaround is underscored by robust R&D commitments, crucial for sustaining innovation and competitiveness in the biotech landscape. The firm's recent CHMP nod for VYVGART® in CIDP treatment further highlights its strategic focus on expanding therapeutic applications, promising continued relevance and impact within the healthcare sector. Click here to discover the nuances of argenx with our detailed analytical health report. Understand argenx's track record by examining our Past report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Believe S.A. is a company that offers digital music services to independent labels and local artists across various regions including France, Germany, the rest of Europe, the Americas, Asia, Oceania, and the Pacific with a market cap of approximately €1.72 billion. Operations: The company's revenue primarily comes from Premium Solutions, generating €924.24 million, while Automated Solutions contribute €64.59 million. Believe, a European tech entity, is navigating its path towards profitability with expected earnings growth of 96.9% annually. Despite current unprofitability, its revenue growth outpaces the French market's average at 13.4% per year compared to 5%. This growth trajectory is supported by strategic moves such as the proposed acquisition by TCMI Inc., EQT X, and Denis Ladegaillerie for a €57.9 million stake, enhancing financial stability and market presence. Moreover, Believe's commitment to R&D aligns with industry demands for continuous innovation, ensuring it remains competitive in the dynamic tech landscape. Get an in-depth perspective on Believe's performance by reading our health report here. Examine Believe's past performance report to understand how it has performed in the past. Simply Wall St Growth Rating: ★★★★★☆ Overview: Comet Holding AG, along with its subsidiaries, delivers X-ray and radio frequency (RF) power technology solutions globally across Europe, North America, and Asia, with a market capitalization of CHF1.79 billion. Operations: The company generates revenue through three main segments: X-Ray Systems (CHF115.89 million), Industrial X-Ray Modules (CHF94.57 million), and Plasma Control Technologies (CHF247.39 million). Comet Holding AG, a Swiss tech firm, is making notable strides with an earnings growth of 37.3% annually, significantly outpacing the local market's average of 10.7%. This robust performance is further underscored by its revenue increase of 12.2% per year, which also surpasses the Swiss market growth rate of 4.2%. Notably, Comet's commitment to innovation is evident in its R&D spending, crucial for maintaining technological leadership in a competitive sector. Recent corporate actions include electing Benjamin Loh as Chairman and approving a dividend increase to CHF 1.50 per share, signaling strong governance and shareholder confidence amidst a promising financial trajectory marked by first-quarter sales surging by 37.5% year-over-year to CHF 111.2 million. Take a closer look at Comet Holding's potential here in our health report. Assess Comet Holding's past performance with our detailed historical performance reports. Dive into all 226 of the European High Growth Tech and AI Stocks we have identified here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTBR:ARGX ENXTPA:BLV and SWX:COTN. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
02-06-2025
- Business
- Yahoo
Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager
Rebecca McLeod brings exceptional U.S. operating experience; most recently served as argenx U.S. General Manager responsible for leading the launch of VYVGART® for gMG and CIDP CAMBRIDGE, Mass., June 02, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today announced that Rebecca McLeod has been appointed to the newly created role of Chief Brand Officer and U.S. General Manager. In this role, she will be responsible for leading the anticipated U.S. commercial launch of apitegromab for patients with SMA – along with establishing the global apitegromab brand strategy and market positioning for Europe, Asia-Pacific and Latin America. "Rebecca's unprecedented experience in building and leading U.S. operations at argenx to launch VYVGART® successfully is invaluable as Scholar Rock accelerates planning toward our anticipated initial launch in SMA this year," said R. Keith Woods, Chief Operating Officer of Scholar Rock. "Launching apitegromab in the U.S. is vital in bringing the potentially transformative benefits of apitegromab to patients with SMA. I am confident that under her leadership, we will deliver for the SMA community in the U.S. and around the world as we become a global leader in developing and delivering innovative therapies to treat patients with rare, severe and debilitating neuromuscular disorders." Ms. McLeod is a 25-year pharmaceutical and biotechnology industry veteran who joins Scholar Rock from argenx, where she led market access, distribution, patient services, medical affairs, operations, marketing and sales for the U.S. organization. Under her leadership, argenx has delivered one of the most successful biopharmaceutical franchise launches with VYVGART. Earlier, she served in several commercial leadership positions across sales, marketing and product management at Alexion Pharmaceuticals and Takeda Pharmaceuticals. "I am thrilled to join Scholar Rock at this pivotal time of scale and growth as we prepare to become a global commercial biotechnology company," said Ms. McLeod. "I'm honored to leverage my leadership experience over the past seven years in the neuromuscular rare disease space to now build and lead Scholar Rock's U.S. operations as we plan to deliver apitegromab for children and adults with SMA, while also rolling out our global apitegromab brand strategy." About Scholar Rock Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily, the company is named for the visual resemblance of a scholar rock to protein structures. Over the past decade, Scholar Rock has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about our approach at and follow @ScholarRock and on LinkedIn. Availability of Other Information About Scholar Rock Investors and others should note that we communicate with our investors and the public using our company website including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website or on X (formerly known as Twitter) or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended. VYVGART® is a trademark of argenx. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Scholar Rock's future expectations, plans and prospects, including without limitation, Scholar Rock's expectations regarding its growth, strategy, the timing and results of regulatory submissions, the therapeutic potential of apitegromab, its transition to a fully integrated global commercial enterprise and planned launch of apitegromab, the establishment of its global brand strategy and the anticipated impact of the leadership appointment described herein. The use of words such as "may," "might," "could," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify such forward-looking statements. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, without limitation, whether the results from the Phase 3 SAPPHIRE trial will be sufficient to support regulatory approval, that preclinical and clinical data, including the results from the Phase 2 or Phase 3 clinical trial of apitegromab, are not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidates; information provided or decisions made by regulatory authorities; competition from third parties that are developing products for similar uses; Scholar Rock's ability to obtain, maintain and protect its intellectual property; Scholar Rock's dependence on third parties for development and manufacture of product candidates including, without limitation, to supply any clinical trials; and Scholar Rock's ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and new business initiatives, and Scholar Rock's ability to continue as a going concern; as well as those risks more fully discussed in the section entitled "Risk Factors" in Scholar Rock's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock's subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock's views only as of today and should not be relied upon as representing its views as of any subsequent date. All information in this press release is as of the date of the release, and Scholar Rock undertakes no duty to update this information unless required by law. View source version on Contacts Scholar Rock: Investors & Media Rushmie NofsingerScholar Rockrnofsinger@ ir@ 857-259-5573 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
01-05-2025
- Business
- Yahoo
Exploring High Growth Tech Stocks In Europe
As European markets experience a notable upswing, with the STOXX Europe 600 Index rising by 2.77% amid easing trade tensions and positive economic signals, investors are increasingly focusing on high-growth tech stocks that show resilience and potential in such dynamic conditions. In this environment, a good stock is often characterized by its ability to adapt to market changes and leverage technological advancements to drive growth, making it a key consideration for those exploring opportunities in Europe's burgeoning tech sector. Name Revenue Growth Earnings Growth Growth Rating Archos 21.07% 36.58% ★★★★★★ Pharma Mar 25.21% 43.09% ★★★★★★ Bonesupport Holding 28.91% 53.88% ★★★★★★ Yubico 20.08% 25.52% ★★★★★★ Elicera Therapeutics 63.53% 97.24% ★★★★★★ Ascelia Pharma 43.57% 70.39% ★★★★★★ CD Projekt 33.78% 37.39% ★★★★★★ XTPL 97.45% 117.95% ★★★★★★ Elliptic Laboratories 49.76% 88.21% ★★★★★★ Xbrane Biopharma 33.71% 82.67% ★★★★★★ Click here to see the full list of 221 stocks from our European High Growth Tech and AI Stocks screener. Let's dive into some prime choices out of from the screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: argenx SE is a commercial-stage biopharmaceutical company focused on developing therapies for autoimmune diseases across multiple international markets, with a market cap of €34.68 billion. Operations: The company generates revenue primarily from its biotechnology segment, amounting to $2.25 billion. It focuses on developing therapies for autoimmune diseases in several key international markets, including the United States, Japan, and China. argenx SE, a trailblazer in the biotech sector, recently showcased its robust growth trajectory with a notable 22.7% annual revenue increase and an impressive leap to profitability, turning a net loss into an $833 million profit within a year. This financial upswing is mirrored by their aggressive R&D investments, crucial for advancing their innovative drug VYVGART® across multiple clinical trials. The recent CHMP nod for VYVGART® in CIDP underlines argenx's commitment to addressing unmet medical needs, potentially boosting future revenues and reinforcing its position in the high-growth biotech landscape of Europe. Take a closer look at argenx's potential here in our health report. Understand argenx's track record by examining our Past report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Remedy Entertainment Oyj is a Finnish video game company focused on developing and selling PC and console games, with a market capitalization of €223.07 million. Operations: The company generates revenue primarily through its computer graphics segment, amounting to €50.66 million. Remedy Entertainment Oyj, amidst a challenging landscape for tech firms, has demonstrated resilience with an 18.9% annual revenue growth, outpacing the Finnish market's average of 3.6%. This growth is underpinned by strategic R&D investments that have positioned the company to transition into profitability within three years, reflecting a robust forecasted annual profit growth of 50.63%. Recently, Remedy provided positive guidance for 2025, expecting increased revenue and operating profits following a significant reduction in net losses from EUR 22.66 million in the previous year to EUR 3.6 million. These developments suggest that despite current unprofitability, Remedy's commitment to innovation and operational improvements could enhance its market position significantly. Unlock comprehensive insights into our analysis of Remedy Entertainment Oyj stock in this health report. Learn about Remedy Entertainment Oyj's historical performance. Simply Wall St Growth Rating: ★★★★★★ Overview: CD Projekt S.A. is a Polish company involved in the development, publishing, and digital distribution of video games for PCs and consoles, with a market cap of PLN23.27 billion. Operations: CD Projekt generates revenue primarily through its CD PROJEKT RED segment, which contributed PLN801.64 million, and adding PLN199.34 million. The company's focus is on video game development and distribution for PCs and consoles in Poland. CD Projekt, navigating through a slight earnings dip with last year's net income falling to PLN 469.87 million from PLN 481.11 million, still shows robust future potential with forecasted revenue and profit growth rates of 33.8% and 37.4% per annum, respectively—significantly outpacing the Polish market's averages. This optimistic outlook is bolstered by a projected Return on Equity of an impressive 40.2% in three years, positioning it well above industry benchmarks and highlighting its effective capital utilization amidst competitive pressures in the gaming sector. Dive into the specifics of CD Projekt here with our thorough health report. Gain insights into CD Projekt's historical performance by reviewing our past performance report. Unlock our comprehensive list of 221 European High Growth Tech and AI Stocks by clicking here. Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive. Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ENXTBR:ARGX HLSE:REMEDY and WSE:CDR. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
28-04-2025
- Business
- Yahoo
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
VYVGART® is first-and-only targeted IgG Fc-antibody fragment for CIDP First novel mechanism of action for CIDP treatment in more than 30 years CHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial European Commission (EC) decision on marketing authorization application (MAA) expected within approximately two months April 28, 2025, 07:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins. 'Our mission is to develop innovative, targeted treatments for patients with rare and severe autoimmune diseases, who continue to face significant unmet needs. The positive CHMP opinion for VYVGART in CIDP brings us one step closer to providing patients across Europe with a transformational new treatment option that provides meaningful functional improvement,' said Luc Truyen M.D., Ph.D., Chief Medical Officer, argenx. 'VYVGART is the first and only targeted IgG Fc-antibody fragment for CIDP and if approved, would mark the first treatment in Europe with a novel, precision mechanism of action for CIDP patients in 30 years.' VYVGART for subcutaneous injection is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional. Treatment is initiated with a weekly dose regimen and may be adjusted to every other week based on clinical evaluation. The CHMP recommendation is based on positive results from the ADHERE clinical trial, the largest study of CIDP patients to date. In the ADHERE study, 66.5% (214/322) of patients treated with VYVGART, regardless of prior treatment, demonstrated evidence of clinical improvement, including improvements in mobility, function and strength. ADHERE met its primary endpoint (p<0.0001) demonstrating a 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in the risk of relapse versus placebo. The study also demonstrated functional improvements across the Inflammatory Neuropathy Cause and Treatment (INCAT) disability scores (>1-point), grip strength (>17 kPa) and I-RODS scale (>8 points) at week 36 compared to baseline at entry to standard of care withdrawal phase. Ninety-nine percent of trial participants elected to participate in the ADHERE open-label extension. The safety results were generally consistent with the known safety profile of VYVGART in previous clinical studies. "For the patient population represented by the European Patient Organisation for Dysimmune and Inflammatory Neuropathies (EPODIN) and for those affected by CIDP, this is excellent news," said Jean-Philippe Plançon, President of EPODIN. "There are still considerable unmet medical needs in the management of CIDP, and the CHMP's recommendation brings renewed hope for improved treatment options and quality of life." The positive CHMP opinion is a scientific recommendation for marketing authorization, serving as a basis for the EC's final decision on argenx's CIDP application for subcutaneous VYVGART. The EC is expected to make a decision following CHMP recommendation and the decision will apply to all 27 European Union Member States, and also to Iceland, Norway and Liechtenstein. Currently, VYVGART is indicated as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive. About ADHERE The ADHERE trial was a multicenter, randomized, double-blind, placebo-controlled trial evaluating SC efgartigimod alfa for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). ADHERE enrolled 322 adult patients with CIDP, 130 of whom were based in Europe, who were off treatment (not on active treatment within the past six months or newly diagnosed) or being treated with immunoglobulin therapy or corticosteroids. The trial consisted of an open-label Stage A followed by a randomized, placebo-controlled Stage B. In order to be eligible for the trial, the diagnosis of CIDP was confirmed by an independent panel of experts. Patients entered a run-in stage, where any ongoing CIDP treatment was stopped and in order to be eligible for Stage A had to demonstrate active disease, with clinically meaningful worsening on at least one CIDP clinical assessment tool, including INCAT, I-RODS, or mean grip strength. Treatment naïve patients were able to skip the run-in period with proof of recent worsening. To advance to Stage B, patients needed to demonstrate evidence of clinical improvement (ECI) with SC efgartigimod alfa. ECI was achieved through improvement of the INCAT score, or improvement on I- RODS or mean grip strength if those scales had demonstrated worsening during the run-in period. In Stage B, patients were randomized to either SC efgartigimod alfa or placebo for up to 48 weeks. The primary endpoint was measured once 88 total relapses or events were achieved in Stage B and was based on the hazard ratio for the time to first adjusted INCAT deterioration (i.e. relapse). After Stage B, all patients had the option to roll-over to an open-label extension study to receive SC efgartigimod alfa. About Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare and serious autoimmune disease of the peripheral nervous system. There is increasing evidence that IgG antibodies play a key role in the damage to the peripheral nerves. People with CIDP experience fatigue, muscle weakness and a loss of feeling in their arms and legs that can worsen over time or may come and go. These symptoms can significantly impair a person's ability to function in their daily lives. Without treatment, one-third of people living with CIDP will need a wheelchair. There are an estimated 31,413 people living with CIDP in the European Union. About EfgartigimodEfgartigimod is an antibody fragment designed to reduce pathogenic immunoglobulin G (IgG) antibodies by binding to the neonatal Fc receptor and blocking the IgG recycling process. Efgartigimod is being investigated in several autoimmune diseases known to be mediated by disease-causing IgG antibodies, including neuromuscular disorders, blood disorders, and skin blistering diseases, in both an IV and SC formulation. SC efgartigimod is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme's ENHANZE® drug delivery technology. In August 2022, efgartigimod received approval from the EC for IV administration as an add on to standard therapy for the treatment of adult patients with gMG who are AChR antibody positive. About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on LinkedIn, Instagram, Facebook, and YouTube. Contacts Media:Kate Dion kdion@ Investors: Alexandra Royaroy@ Forward-Looking Statements The contents of this announcement include statements that are, or may be deemed to be, 'forward-looking statements.' These forward-looking statements can be identified by the use of forward-looking terminology, including the terms 'aim,' 'are,' 'believe,' 'can,' 'continue,' 'expect,' 'may,' and 'will' and include statements argenx makes concerning the expected timing and decision of the EC regarding VYVGART for SC injection for CIDP treatment and the application of such decision; the potential for improved treatment options and quality of life; and its goal of translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including but not limited to, the results of argenx's clinical trials; expectations regarding the inherent uncertainties associated with the development of novel drug therapies; preclinical and clinical trial and product development activities and regulatory approval requirements; the acceptance of its products and product candidates by its patients as safe, effective and cost-effective; the impact of governmental laws and regulations, including tariffs, export controls, sanctions and other regulations on its business; its reliance on third-party suppliers, service providers and manufacturers; inflation and deflation and the corresponding fluctuations in interest rates; and regional instability and conflicts. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by in to access your portfolio
